Favourable improvement in haematological parameters in response to oral iron and vitamin C combination in children with Iron Refractory Iron Deficiency Anemia (IRIDA) phenotype

Blood Cells Mol Dis. 2019 Mar:75:26-29. doi: 10.1016/j.bcmd.2018.12.002. Epub 2018 Dec 13.

Abstract

Treatment in IRIDA focuses on use of intravenous iron preparations to circumvent oral absorptive defect resulting from high levels of hepcidin due to TMPRSS6 gene variations. However, recent case reports and recommendations on atypical microcytic hypochromic anemias advocate use of oral iron and vitamin c trial before parenteral iron, as the same results in comparable improvement in haemoglobin. We prospectively evaluated our IRIDA cohort (n = 7) with oral iron and vitamin c dose over a period of 10 weeks and noted complete response in majority (6/7 = 86%) with >2 g/dL rise in Hb along with significant improvement of other iron related indices.

Keywords: IRIDA; Iron; RBC indices; Ret-He; Vitamin c.

MeSH terms

  • Administration, Oral
  • Adolescent
  • Anemia, Hypochromic / drug therapy
  • Anemia, Iron-Deficiency / drug therapy*
  • Ascorbic Acid / administration & dosage*
  • Child
  • Child, Preschool
  • Drug Therapy, Combination
  • Female
  • Hemoglobins / drug effects*
  • Humans
  • Iron / administration & dosage*
  • Male
  • Phenotype

Substances

  • Hemoglobins
  • Iron
  • Ascorbic Acid

Supplementary concepts

  • Anemia, hypochromic microcytic
  • Iron-Refractory Iron Deficiency Anemia